XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Sep. 30, 2024
Dec. 31, 2023
Current assets:        
Cash and cash equivalents [note 5] $ 13,016 $ 12,753    
Marketable securities [note 5] 10,229 21,607    
Prepaid expenses and other assets 1,755 2,107    
Total current assets 25,000 36,467    
Other assets and restricted cash [note 5] 300 39    
Right-of-use assets [note 8] 106 119    
License agreement [note 5 and note 6] 918 974    
Goodwill 1,034 1,034    
Total assets 27,358 38,633    
Current liabilities:        
Accounts payable 1,656 1,950    
Accrued liabilities other 1,304 573    
Accrued clinical liabilities 1,955 1,077    
Accrued compensation 964 3,027    
Current portion of long-term obligations [note 8] 57 55    
Current portion of convertible debt [note 5 and note 6] 1,194 0    
Total current liabilities 7,130 6,682    
Non-current portion of convertible debt [note 5 and note 6] 8,657 9,837    
Contingent consideration [note 4 and note 5] 1,240 1,149    
Long-term obligations [note 8] 52 66    
Total liabilities 17,079 17,734    
Commitments and contingencies [note 8]    
Stockholders' equity:        
Common stock, $0.001 par value, 150,000,000 shares authorized, 34,685,072 issued and outstanding at March 31,2025 and 34,685,072 issued and outstanding at December 31, 2024 103 103    
Additional paid-in capital 228,575 226,343    
Accumulated deficit (218,405) (205,578)    
Accumulated other comprehensive income 6 31    
Total stockholders' equity 10,279 20,899   $ (1,448)
Total liabilities and stockholders' equity 27,358 38,633    
Series A Convertible Preferred Stock [Member]        
Stockholders' equity:        
Convertible preferred stock, value    
Series B Convertible Preferred Stock [Member]        
Stockholders' equity:        
Convertible preferred stock, value